MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. Kaushik J. Dave

MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. 
Kaushik J. Dave 
ATLANTA, GA -- (Marketwired) -- 01/30/14 --  MissionIR today
announces the online availability of its interview with Actinium
Pharmaceuticals, Inc. (OTCQB: ATNM) president and Chief Executive
Officer Dr. Kaushik J. Dave, a 25-year veteran with extensive biotech
and pharmaceutical experience. The full audio interview is available
at the following link: http://ATNM.MissionIR.com/interview.html.  
Actinium is a biotech company leveraging modern science and its
proprietary platform to develop and commercialize groundbreaking
therapies for treatment in different types of cancer that currently
do not have any approved treatment.  
Iomab-B is the company's lead program for bone marrow conditioning in
patients with acute myeloid leukemia (AML) who do not have any
curative treatment options. Iomab-B is poised to start a pivotal
phase 3 study, backed by significant data from five completed phase 1
and phase 2 clinical trials.  
"This program has the potential to disrupt the field of bone marrow
transplant, and as a consequence, has attracted a significant amount
of interest from the medical community," Dr. Dave stated in the
interview. 
Actinium's pipeline also includes Actimab-A, currently in phase
1/phase 2 clinical studies as a primary induction treatment of AML.
The company's business model is to leverage its expertise and strong
partnerships with leading cancer institutions to further the
development of these drug candidates. 
Dr. Dave detailed his education and extensive background in the
pharmaceutical industry and drug development, noting that his
interest in joining Actinium stemmed from recognizing the company's
"significant unrealized potential for growth." Dr. Dave also briefly
touched on the blended expertise of the rest of Actinium's leadership
and board of directors. 
"These folks, all of them, bring complementary skills... all of which
make our team well-equipped to face challenges of a rapidly ascending
biotech company," he stated.  
In 2013, Actinium achieved several important milestones, as explained
by Dr. Dave in the interview, which have positioned the company to
reach several key objectives in 2014, including:  


 
--  Iomab-B poised to start phase 3
--  Interim phase 2 results for Actimab-A
--  Uplist to Nasdaq or NYSE exchange
--  Obtaining additional analyst coverage
--  Establish strategic collaborations

  
Wrapping up the interview, Dr. Dave explained Actinium position in the
biotech industry, how it is raising awareness in the investment
community, and the company's recent private placement of
approximately $6.6 million in gross proceeds, which is allocated
toward achieving the company goals for the year.  
About Actinium Pharmaceuticals, Inc.  
Actinium Pharmaceuticals, Inc. is a New York-based biopharmaceutical
company developing innovative targeted payload immunotherapeutics for
the treatment of advanced cancers. Actinium's targeted radiotherapy
is based on its proprietary delivery platform for the therapeutic
utilization of alpha-emitting actinium-225 and bismuth-213 and
certain beta emitting radiopharmaceuticals in conjunction with
monoclonal antibodies. The Company's lead radiopharmaceutical
Iomab(TM)-B will be used in preparing patients for hematopoietic stem
cell transplant, commonly referred to as bone marrow transplant. The
Company is conducting a single, pivotal, multicenter Phase 3 clinical
study of Iomab(TM)-B in refractory and relapsed Acute Myeloid
Leukemia (AML) patients over the age of 55 with a primary endpoint of
durable complete remission. The company's second program, Actimab-A,
is continuing its clinical development in a Phase 1/2 trial for newly
diagnosed AML patients over the age of 60 in a single-arm multicenter
trial.  
For additional information, please visit the Company's corporate
Website: www.ActiniumPharmaceuticals.com  
This press release may contain "forward-looking statements."
Expressions of future goals and similar expressions reflecting
something other than historical fact are intended to identify
forward-looking statements, but are not the exclusive means of
identifying such statements. These forward-looking statements may
include, without limitation, statements about our market opportunity,
strategies, competition, expected activities and expenditures as we
pursue our business plan. Although we believe that the expectations
reflected in any forward-looking statements are reasonable, we cannot
predict the effect that market conditions, customer acceptance of
products, regulatory issues, competitive factors, or other business
circumstances and factors described in our filings with the
Securities and Exchange Commission may have on our results. The
company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this press release. 
Actinium Pharmaceuticals 
New York, NY
www.ActiniumPharmaceuticals.com 
646-459-4201
CSohmer@ActiniumPharmaceuticals.com  
Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com 
 
 
Press spacebar to pause and continue. Press esc to stop.